Atomoxetine: 4 agencies, 2008–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 11.3 years, from 21 Feb 2008 at PHARMAC (New Zealand) to 19 Jun 2019 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: recommended on 11 Nov 2013, restricted by 7 Dec 2015.
No assessment is on file from HAS (France), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2019; on this evidence the file is dormant.
5 distinct indication wordings are recorded for atomoxetine by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess atomoxetine, on 21 Feb 2008; PBAC (Australia) did not open a file until 2016 — an unusually long tail of 8.4 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 4 agencies here assessed atomoxetine more than once, PHARMAC (New Zealand) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed atomoxetine.
The full ledger for atomoxetine reads 4 recommended, 1 advice, 1 other and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 19 Jun 2019 | Removal of funding restrictions | funding application decided · decision reached | source |
| PBAC (Australia) | 2016 | Attention-deficit hyperactivity disorder | The PBAC considered the restriction for atomoxetine should be updated to include lisdexamf… | source |
| SMC (Scotland) | 7 Dec 2015 | treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme… | accepted (restricted) | source |
| AWMSG (Wales) | 19 Jun 2015 | Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adu… | outside AWMSG criteria | source |
| AWMSG (Wales) | 27 Feb 2014 | Initiation of treatment in adults with attention deficit hyperactivity disorder (ADHD) | recommended (full) | source |
4 further decisions for atomoxetine, across 2 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- guanfacine — divergent outcome (recommended vs not recommended) on a shared indication
- methylphenidate — same ATC class N06B — Psychoanaleptics
- idebenone — same ATC class N06B — Psychoanaleptics
- solriamfetol — same ATC class N06B — Psychoanaleptics
- piracetam — same ATC class N06B — Psychoanaleptics
- lisdexamfetamine — same ATC class N06B — Psychoanaleptics
Coverage: 9 decisions for atomoxetine from 4 agencies, 2008 to 2019. Data to 7 Sep 2026. ATC class N06B — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.